AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
Non-small cell lung cancer with EGFR mutations are known to develop resistance to EGFR tyrosine kinase inhibitors. Here, the authors show AURKB activation to be associated with resistance in EGFR mutant lung cancer cells, and that AURKB is a therapeutic target in resistant tumours that lack the p.T7...
Guardado en:
Autores principales: | Jordi Bertran-Alamillo, Valérie Cattan, Marie Schoumacher, Jordi Codony-Servat, Ana Giménez-Capitán, Frédérique Cantero, Mike Burbridge, Sonia Rodríguez, Cristina Teixidó, Ruth Roman, Josep Castellví, Silvia García-Román, Carles Codony-Servat, Santiago Viteri, Andrés-Felipe Cardona, Niki Karachaliou, Rafael Rosell, Miguel-Angel Molina-Vila |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/34f8c0286b2b4c818818bdd02b7b3019 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
por: Kirstine Jacobsen, et al.
Publicado: (2017) -
Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
por: Mikkel G. Terp, et al.
Publicado: (2021) -
Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
por: Karachaliou N, et al.
Publicado: (2014) -
AURKB as a Promising Prognostic Biomarker in Hepatocellular Carcinoma
por: Jingchuan Xiao, et al.
Publicado: (2021) -
Calidad : metodología para documentar el ISO 9000 versión 2000 /
por: Servat, Alberto Alexander
Publicado: (2005)